VBL Therapeutics Appoints Alison Finger and Michael Rice to its Board of Directors
08 juil. 2021 07h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, July 08, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the appointments of Alison Finger and Michael Rice to its Board of Directors, effective July 7,...
VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
15 juin 2021 07h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, June 15, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today provided an update on its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the...
VBL Therapeutics Announces Addition of Progression Free Survival as a Second Primary Endpoint in OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
03 juin 2021 07h00 HE
|
VBL Therapeutics
Second primary endpoint added following discussion with the U.S. Food and Drug AdministrationSuccessfully meeting either PFS or OS primary endpoints expected to be sufficient for submitting a BLA for...
VBL Therapeutics to Provide an Update on the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
20 mai 2021 07h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, May 20, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that a poster providing an update on the OVAL Phase 3 registration enabling clinical trial of...
VBL Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
11 mai 2021 07h00 HE
|
VBL Therapeutics
Conference Call and Webcast at 8:30 a.m. EDT Today OVAL Phase 3 registration-enabling study investigating VB-111 in patients with platinum-resistant ovarian cancer remains on track in spite of...
VBL Therapeutics to Report First Quarter Financial Results on May 11
04 mai 2021 07h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, May 04, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) will release its first quarter financial results for the period ended March 31, 2021 on Tuesday, May 11, 2021...
Vascular Biogenics Ltd. Closes Public Offering of Ordinary Shares and Pre-Funded Warrants
14 avr. 2021 06h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, April 14, 2021 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT), today announced the closing of its underwritten public offering...
Vascular Biogenics Ltd. Prices Public Offering of Ordinary Shares and Pre-Funded Warrants
09 avr. 2021 08h58 HE
|
VBL Therapeutics
TEL AVIV, Israel, April 09, 2021 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT), today announced the pricing of an underwritten public offering of...
Vascular Biogenics Ltd. Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
08 avr. 2021 16h05 HE
|
VBL Therapeutics
TEL AVIV, Israel, April 08, 2021 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT), today announced that it intends to offer and sell ordinary shares...
VBL Therapeutics to Host Virtual R&D Day on April 6
30 mars 2021 07h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, March 30, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that it will host a virtual R&D Day for analysts and investors beginning at 10:00am ET on...